Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 494 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... October 19, 2021 Cancer and the Holidays December 3, 2021 Research with integrity – why building networks is vital for integrity March 22, 2023 Hospital Mistakenly Gave Woman a Mastectomy, Then Postponed Her Reconstruction for... July 12, 2021 Load more HOT NEWS ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays... Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS... Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From...
